1. Talked towards the beginning of the presentation of partnering ARRY-520 and/or ARRY-614 geographically (offered possibility of ex-U.S. partnering before). Not sure if this means increased discussions on this front. Conversely, ARRY-797 partnering timing seems to have been pushed back as I believe the guidance now was just "by the end of the year" whereas previously there seemed to be guidance for mid-2013.
2. Have hit MTD on ARRY-614 and will move into expansion cohort at the selected dose in a "refined target population." Not really made clear what is meant by "refined target population." Also, sounds like will have data to inform potential Phase 3 trial design by the end of this year. Seems like timing for 614 program has been pushed back a bit as I thought previously the expectation was to have the key data in mid-2013.
3. Appears that ARRY-520 is still on track for data around mid-2013 to inform potential Phase 3 trial design.
4. Selumetinib is advancing in 65 trials (39 Phase 2).
Market Data 
Markets 
AI
